- Home
- LICN vs QLGN Comparison
LICN vs QLGN Comparison
Compare LICN & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICN
- QLGN
- Stock Information
- Founded
- LICN 2004
- QLGN 1996
- Country
- LICN China
- QLGN United States
- Employees
- LICN N/A
- QLGN N/A
- Industry
- LICN
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- LICN
- QLGN Health Care
- Exchange
- LICN Nasdaq
- QLGN Nasdaq
- Market Cap
- LICN 3.1M
- QLGN 3.1M
- IPO Year
- LICN 2023
- QLGN N/A
- Fundamental
- Price
- LICN $4.85
- QLGN $2.00
- Analyst Decision
- LICN
- QLGN
- Analyst Count
- LICN 0
- QLGN 0
- Target Price
- LICN N/A
- QLGN N/A
- AVG Volume (30 Days)
- LICN 88.2K
- QLGN 39.7K
- Earning Date
- LICN 01-01-0001
- QLGN 08-14-2025
- Dividend Yield
- LICN N/A
- QLGN N/A
- EPS Growth
- LICN N/A
- QLGN N/A
- EPS
- LICN N/A
- QLGN N/A
- Revenue
- LICN $41,477,000.00
- QLGN N/A
- Revenue This Year
- LICN N/A
- QLGN N/A
- Revenue Next Year
- LICN N/A
- QLGN N/A
- P/E Ratio
- LICN N/A
- QLGN N/A
- Revenue Growth
- LICN 4.32
- QLGN N/A
- 52 Week Low
- LICN $2.60
- QLGN $1.61
- 52 Week High
- LICN $462.00
- QLGN $10.45
- Technical
- Relative Strength Index (RSI)
- LICN 53.01
- QLGN 51.54
- Support Level
- LICN $4.16
- QLGN $1.66
- Resistance Level
- LICN $5.76
- QLGN $2.16
- Average True Range (ATR)
- LICN 0.45
- QLGN 0.10
- MACD
- LICN 0.03
- QLGN 0.07
- Stochastic Oscillator
- LICN 38.75
- QLGN 68.16
About LICN Lichen China Limited
Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.